COVID Vaccine Immune Response In Hemodialysis Patients Immune response in HD patients
Main Article Content
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in chronic kidney disease patients, especially those on maintenance hemodialysis (HD). The comparison of immunogenicity of different COVID vaccines in the dialysis populations is lacking especially in the middle east region.
Methods: We conducted a retrospective observational study, that includes 164 hemodialysis patients (HD) and 54 health workers (HW), who received 2 doses of either Pfizer-BioNTech or Sinopharm vaccine. The primary endpoint was to report the rate of seroconversion and the factors affecting it.
Results: HD patients have a significantly low seroconversion rate than HW (HD vs HW: 76.54% and 100%, p=<0.05), also S1 IgG antibody level was significantly low in HD patients (HD vs HW: 183.5 and 400 BAU/ml, p=<0.05). The type of vaccine and hypo-response to the HBV vaccine were two statistically significant factors affecting the seropositivity rate in HD patients. As compared to Sinopharm, Pfizer-BioNTech vaccinated HD patients exhibit not only higher seroconversion rate (Pfizer-BioNTech vs Sinopharm: 90.80% and 60%, p=<0.05) but also express high S1 antibody titer (Pfizer-BioNTech vs Sinopharm: 425 and 162 BAU/ml (p=<0.05), however, there is no significant difference in post-vaccine COVID infection rate among the two vaccines (Pfizer-BioNTech vs Sinopharm: 39.24% and 42.22% (p= 0.176).
Conclusion: Lower Immune response to the COVID vaccine is observed in HD patients as compared to HW participants, also Pfizer-BioNTech vaccinated HD patients exhibit better seroconversion rates and higher antibody titer than Sinopharm vaccine in HD patients, so alternative vaccine strategies should be designed in dialysis patients.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Chen JJ, Lee TH, Tian YC, Lee CC, Fan PC, Chang CH. Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease. JAMA Network Open. 2021;4(10):e2131749. doi:https://doi.org/10.1001/jamanetworkopen.2021.31749.
3. Pitchou Kengibe, J.R. Makulo, Yannick Mayamba Nlandu, et al. Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study. 2019;34. doi:https://doi.org/10.11604/pamj.2019.34.122.19603
4. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney International. Published online March 2020. doi:https://doi.org/10.1016/j.kint.2020.03.001
5. Cancarevic I, Nassar M, Daoud A, et al. Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis. World journal of virology. 2022;11(5):352-361. doi:https://doi.org/10.5501/wjv.v11.i5.352)
6. DaRoza G, Loewen A, Ognjenka Djurdjev, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. American Journal of Kidney Diseases. 2003;42(6):1184-1192. doi:https://doi.org/10.1053/j.ajkd.2003.08.019
7. Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology. Published online April 6, 2021:CJN.03500321. doi:https://doi.org/10.2215/cjn.03500321
8. Chiew Tong NK, Beran J, Kee SANN, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney International. 2005;68(5):2298-2303. doi:https://doi.org/10.1111/j.1523-1755.2005.00689.x
9. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine. 2005;23(30):3957-3960. doi:https://doi.org/10.1016/j.vaccine.2005.02.033
10. Taji L, Thomas D, Oliver MJ, et al. COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ. 2021;193(8):E278-E284. doi:https://doi.org/10.1503/cmaj.202601
11. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney International. 2020;98(6):1540-1548. doi:https://doi.org/10.1016/j.kint.2020.09.006
12. Ram DKN, Gulzar K, Alalawi F, Ahmed M, Manuel R, Alhadari A. COVID-19 infection in hemodialysis patients, incidence, risk factors and mortality. Single Centre Study. New Emirates Medical Journal. 2022;03. doi:https://doi.org/10.2174/03666220817145707
13. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The Use of Vaccines in Adult Patients With Renal Disease. American Journal of Kidney Diseases. 2005;46(6):997-1011. doi:https://doi.org/10.1053/j.ajkd.2005.08.032
14. Murt A, Dinc HO, Altiparmak MR, et al. Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity. Nephron. 2022;146(6):559-563. doi:https://doi.org/10.1159/000524658
15. Clavero R, Parra-Lucares A, Méndez-Valdés G, et al. Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. 2022;10(9):1542-1542. doi:https://doi.org/10.3390/vaccines10091542
16. Alqassieh R, Suleiman A, Abu-Halaweh S, et al. Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines. 2021;9(11):1223. doi:https://doi.org/10.3390/vaccines9111223
17. Kislaya I, Rodrigues EF, Borges V, et al. Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants. Emerging Infectious Diseases. 2022;28(2):331-337. doi:https://doi.org/10.3201/eid2802.211789
18. Sanders JSF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation. 2021;106(4):821-834. doi:https://doi.org/10.1097/tp.0000000000003983
19. Angel-Korman A, Peres E, Bryk G, et al. Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. Clinical Kidney Journal. Published online October 12, 2021. doi:https://doi.org/10.1093/ckj/sfab206)
20. Danthu C, Hantz S, Dahlem A, et al. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Journal of the American Society of Nephrology. 2021;32(9):2153-2158. doi:https://doi.org/10.1681/asn.2021040490
21. Van Praet J, Reynders M, De Bacquer D, et al. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. Journal of the American Society of Nephrology. 2021;32(12):3208-3220. doi:https://doi.org/10.1681/asn.2021070908
22. Nagappa B, Marimuthu Y. Seroconversion Rate and Diagnostic Accuracy of Serological Tests for Coronavirus 2019. Clinical Infectious Diseases. Published online May 30, 2020. doi:https://doi.org/10.1093/cid/ciaa676